

Sorbonne University Master 2 BMC - Systems Immunology

Characterization of neutrophil populations associated with osteosarcoma and association with the tumor's inflammatory status

By

HUYNH Minh-Anh

September 2022

Table of Contents

| 1 | Introduction | 1 | | | |
|---|---|----|--|--|--|
| 2 | Objective and experimental principle | | | | |
| 3 | Methods | | | | |
| | 3.1 MDS Clustering | 6 | | | |
| | 3.2 Differential Expression Gene analysis | 6 | | | |
| 4 | Results | 7 | | | |
| | 4.1 Creation of inflammatory groups | 7 | | | |
| 5 | Discussion | 10 | | | |
| 6 | Bibliography | 11 | | | |
| 7 | Appendix: code | | | | |

List of Abbreviations

- DEG : Differentially Expressed Genes
- MDS: MultiDimensional Scaling
- TME: Tumor MicroEnvironment
- UMAP : Uniform Manifold Approximation and Projection for Dimension Reduction

Acknowledgements

Thank you for following this tutorial!

I hope you'll find it useful to write a very professional dissertation.

1 Introduction

- introduce the reader to the subject area and clarify the knowledge gap that the dissertation research will fill.
- set the context for the dissertation by reviewing the relevant literature.
- include relevant references to general (theoretical papers and reviews) and specific (specific to the particular question addressed) literature, to justify the research that has been undertaken and define the questions being addressed.
- state the primary research questions and hypotheses in the final paragraph.
- follow an 'inverted triangle' format, progressing from general scientific ideas and why they matter to the specific research questions addressed in the dissertation project.

(Khatami, 2014)

The introduction should not be just a 'Literature Review.'

Recently, single-cell RNA sequencing (scRNA-seq) has shown its potential in exploring the tumor microenvironment (TME), in order to explore intra-tumor heterogeneity and cellular dialogue with the tumor cells.

Neutrophils are the first innate immune cells recruited during an inflammation and are known to be a main player regarding the worsening of cancer. Neutrophils are first recruited to the TME, through CXCR2 ligands chemokines (CXCL1, CXCL2, CXCL5). Pro-tumor neutrophils support cancer cells initiation cells by releasing reactive oxygen species (ROS), RNS and proteases, and enabling a variety of action, such as angiogenesis, protecting tumor cells from antimicrobial factors via NETs, preventing CD8+ T cell activity through iNOS, arginase 1 secretion (Long et al., 2021), and facilitation of metastasis through NK cell suppression and escorting tumor cells.

Epidemiology Extraskeletal osteosarcoma accounts for < 1% of all soft tissue sar-

comas and approximately 4% of all osteosarcomas. It typically arises during midlife and late adulthood, with most patients being in the fifth to seventh decades of life at diagnosis; occurrence in children is uncommon. Males may be affected more frequently than females (M:F ratio: 0.8-19:1).

copy-number losses in tumour suppressor genes (CDKN2A, TP53, RB1, PTEN, NF1, LSAMP); gains and amplifications M oncogenes (RUNX2, CDC5L, COPS3, EGFR, MDM2, CD PMP22, mutations involving tumour suppressor genes (TP53. PTEN, RB1, NF1, SMARCA4), chromatin-remodelling genes (ATRX, DAXX, BRCA1, DAXX2, CHEK2, ARID5B), histone methylation and demethylation genes (BCOR, DNMT3A, MKK3 [MAP2K3]), and WNT/|3-catenin and sonic hedgehog pathway genes (AMER1, AXIN2, GSK3B, GLI1, NOTCH3); and in some cases TERT promoter mutation and PIK3CA mutations have been reported. The genomic signature of this tumour shows features overlapping those of conventional skeletal osteosarcoma.

Conventional osteosarcomas (COSs) can arise in any bone, but the vast majority originate in the long bones of the extremities, most commonly in the distal femur (30%), followed by the proximal tibia (15%) and the proximal humerus (15%), i.e. sites of the most proliferative growth plates. In long bones, the tumour is usually metaphyseal (90%) and only infrequently develops in the diaphysis (9%) or rarely in the epiphysis. The jaws are the fourth most common site of origin. Involvement of the small bones of the extremities and multifocal osteosarcoma, either synchronous or metachronous, are rare, the latter representing metastatic spread rather than multiple independent primary tumours. Telangiectatic osteosarcomas (TAEOSs) also frequently develop around the knee (-60%) and in the proximal humerus (-20%) (116). They occur in the metaphysis, commonly with direct extension into the adjacent epi-

physis and diaphysis. Small cell osteosarcoma (SCOS) has a similar disMbution but more commonly develops in the diaphysis of long bones (10-15%).

syndrome, who have an increased incidence of osteosarcoma. Patients with hereditary retinoblastoma also have a high risk of developing osteosarcoma , in particular after receiving ionizing radiation therapy. The genes causing these syndromes are also the most commonly mutated genes in sporadic osteosarcoma JP53 in > 90% and RB1 in as many as 56% of cases). Germline mutations in various RECQ helicases underlie another group of rare syndromes associated with COS, including Bloom syndrome (BLM [FIECQL3]), Werner syndrome (WRN), and Rothmund—Thomson syndrome (RECQL4). Acquiring chromosomal instability is also the hallmark of sporadic COS and probably the most crucial step for initiating and driving tumour development. Syndrome-related COSs have been recognized for a long time, but the increasing use of DNA sequencing for genotyping neoplasms and also the germline of individuals has identified pathogenic germline mutations in as many as 17.9% of COSs in larger studies, a figure that is likely to increase in sequencing studies to come.

There is general consensus about recurring amplifications for some regions, such as gains of chromosome arms 6p (40- 50% of cases, harbouring RUNX2, VEGFA, E2F3, and CDC5L [CDC5]), 8q (45-55% of cases, harbouring MYC), and 17p, which have been detected by classic karyotyping and conventional comparative genomic hybridization, as well as deep sequencing. However, studies are difficult to compare because the definition of a recurrent alteration varies . The TP53 antagonist MDM2 is amplified in about 10% of cases, suggesting a pre-existing central low-grade osteosarcoma that underwent dedifferentiation in at least a subset of cases . FGFR1 amplifications have been demonstrated in 18.5% of cases; alterations in the IGF1R signalling pathway were observed 14% of COSs . Homozygous loss of CDKN2A oc-

curs in 10% of COSs, is associated with an adverse outcome, and has been implicated in osteosarcoma development from a mesenchymal progenitor. RB1 is deleted in about 50% of osteosarcomas. Other recurrently deleted genes include LSAMP, DLG2, and WWOX. Distinct patterns of large-scale transitions and loss of heterozygosity reminiscent of that seen in BRCA11 BF1CA2-deV have been identified in COS, suggesting a deficiency in homologous recombination repair (socalled BRCAness). These findings indicate a potential sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors

Gene expression profiling demonstrated an association between macrophage expression profiles and lack of metastases, suggesting a beneficial effect of macrophage infiltration. These findings have also been confirmed by immunohistochemical analysis. A number of genes have been demonstrated to be hypermethylated in COS, affecting transcriptional activity HIC1, WIF1, PHLDA2 (TSSC3), RASSF1 (RASSF1A), GADD45. and RUNX2 {1571}. Methylation of ER (ESR1) seems particularly interesting, because this steroid receptor is involved in osteoblastic differentiation. Relieving ESR1 hypermethylation by DNA methyltransferases resulted in growth inhibition of tumour cells

COS has a broad immunoprofile that lacks diagnostic specificity. Commonly expressed antigens include SATB2, osteocalcin (BGLAP), osteonectin (SPARC), osteoprotegerin (TNFRSF11B), RUNX2, S100, actins, and CD99. Importantly (because it is a diagnostic pitfall), osteosarcomas may also express keratin and EMA. Tumour cells are generally negative for CD31, CD45, and FOS, with FOS representing a relatively recent surrogate marker for the FOSgene rearrangements typically observed in osteoid osteoma and osteoblastoma (1012,91A,1739A). FOS immunohistochemistry might also be helpful in d ifferentiating osteoblastoma and osteoblastomalike

osteosarcoma. TAEOS and SCOS have an immunophenotype similar to that of COS. SATB2 is regarded as a very sensitive marker for osteoblastic differentiation but lacks specificity

2 Objective and experimental principle

Previously, the lab has demonstrated that tumor stem cells have specific properties inside the tumor, characterized by the calpaïne 6 biomarker. This cell is capable of coordinating invasion of distant tissues and confers to the whole tumor a specific phenotype.

The study aims to analyze public dataset and to make a custom analysis using NicheNet in order to understand the cellular crosstalk and interactions in the TME, between neutrophils and tumor cells, more specifically, calpaïne 6 tumor stem cells.

Collaborating with Dr Jean-Marc Schwartz's team in Manchester and a M2 in systems biology, bioinformatics, collecting data from available open-source studies, we will perform a customized downstream analysis on GSE87686 and TargetOS, PEM-RBOSARC and a scRNAseq dataset in order to identify the relationships between neutrophils and osteosarcoma through the use of genetic signatures available from MSigDB and customized gene lists.

NicheNet to identify ligand activity and identify receptors, and predict their targeted consequences.

3 Methods

Protocol similar to SkeletalVis(Soul et al., 2019)

Data normalization via TPM method by Kallisto (?), TPM is the best normalization method (Abrams et al., 2019).

DESeq2, differential expression gene analysis, representation through heatmap and volcano plot

Citer: Love, M.I., Huber, W., Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15:550. 10.1186/s13059-014-0550-8

Data visualization with UMAP, k-means clustering,

Using EnrichR package for functional gene enrichment/pathway analysis, querying "GO_Molecular_Function_2021," "Human_Gene_Atlas," "BioPlanet_2019," "GO_Biological_Process_2021," "GO_Cellular_Component_2021"

Gene signatures used from MSigDB:

HAY_BONE_MARROW_NEUTROPHIL.v7.5.1

Use NicheNet R package

3.1 MDS Clustering

3.2 Differential Expression Gene analysis

Differentially Expressed Genes (DEG)

4 Results

Some more guidelines from the School of Geosciences.

This section should summarize the findings of the research referring to all figures, tables and statistical results (some of which may be placed in appendices).

- include the primary results, ordered logically it is often useful to follow the same order as presented in the methods.
- alternatively, you may find that ordering the results from the most important to the least important works better for your project.
- data should only be presented in the main text once, either in tables or figures; if presented in figures, data can be tabulated in appendices and referred to at the appropriate point in the main text.

Often, it is recommended that you write the results section first, so that you can write the methods that are appropriate to describe the results presented. Then you can write the discussion next, then the introduction which includes the relevant literature for the scientific story that you are telling and finally the conclusions and abstract – this approach is called writing backwards.

4.1 Creation of inflammatory groups

Inflammatory groups characterizing the intensity of inflammatory status in tumors were created by choosing the lowest and highest mean of Z-score of the hallmark inflammatory response signature from MSigDB, containing 200 genes. ICAM4 was notably not present in the dataset in TARGET-OS cohort. The groups were cut off evenly using the *ntile* function in *dplyr* R package.




Figure 1: Histogram

Those manually defined groups correspond fairly well to functional groups, defined by k-means clustering based on MDS visualization (**Figure 1**).

5 Discussion

the purpose of the discussion is to summarise your major findings and place them in the context of the current state of knowledge in the literature. When you discuss your own work and that of others, back up your statements with evidence and citations.

- The first part of the discussion should contain a summary of your major findings
 (usually 2 4 points) and a brief summary of the implications of your findings.
 Ideally, it should make reference to whether you found support for your hypotheses or answered your questions that were placed at the end of the introduction.
- The following paragraphs will then usually describe each of these findings in greater detail, making reference to previous studies.
- Often the discussion will include one or a few paragraphs describing the limitations of your study and the potential for future research.
- Subheadings within the discussion can be useful for orienting the reader to the major themes that are addressed.

6 Bibliography

Khatami, M. (2014). Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis! Cancers 6, 297–322.

7 Appendix: code

All analysis was done using R software. Code is available at https://github.com/Minh-AnhHuynh/Osteosarcoma-Project

Summary

English Summary